Efficacy and Tolerance Evaluation of an Injective Treatme... | NCT03881189

NCT03881189

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Status Module

Description Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
SUNEKOS ® 200	Experimental	The 1st intradermal treatment (T1i) with "Sunekos ® 200" was carried out during the basal visit (T0), after basal evaluations planned by the study procedure, and then repeated 2 more times with an interval of 15 days (T2i and T3i)	Device: SUNEKOS® 200

Interventions

Name	Type	Description	Arm Group Labels	Other Names
SUNEKOS® 200	Device	The intradermal injection procedure was performed bilaterally, on the area around the eyes including the eyelids, using periosteal and subepidermal injection techniques. This injective procedure consists of micro-wheals of 0.2 ml just above the periosteum and micro-wheals of 0.1 ml very superficially, just under epidermis.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Change from baseline of wrinkles grade around the eyes	Visual score of crow's feet, according to a reference photographic scale from 0 (no wrinkles) to 7 (very marked wrinkles)	T0 (baseline), T3i+1 (1 day after the 3rd injection treatment with Sunekos 200), T2M (after 2 months), T3M (after 3 months)
Change from baseline of dark circles grade	Visual score of dark circles grade, according to a reference photographic scale from 0 (absent) to 4 (very marked)	T0 (baseline), T3i+1 (1 day after the 3rd injection treatment with Sunekos 200), T2M (after 2 months), T3M (after 3 months)
Change from baseline of roughness profilometric parameters	Crow's feet profilometric parameters measured by Primos compact portable device (GFMesstechnik). Ra is average roughness of the analysed profile, Rt is wrinkles total high, Rv is wrinkles maximum depth.	T0 (baseline), T3i+1 (1 day after the 3rd injection treatment with Sunekos 200), T2M (after 2 months), T3M (after 3 months)
Change from baseline of dark circles colorimetric parameters	Dark circles colorimetric measured by Chroma Meter CR-200® . L* represent the lightness of the colour, a* represent the red component of the colour, b* represent the dark component of the colour	T0 (baseline), T3i+1 (1 day after the 3rd injection treatment with Sunekos 200), T2M (after 2 months), T3M (after 3 months)
Change from baseline of spectrophotometrical value	Dark circles spectrophotometrical color value measured by a visible-UV-IR spectrophotometer	T0 (baseline), T3i+1 (1 day after the 3rd injection treatment with Sunekos 200), T2M (after 2 months), T3M (after 3 months)

Secondary Outcomes

Measure	Description	Time Frame
change from of photographic documentation	Photographic documentation of the area around the eyes	T0 (baseline), T3i+1 (1 day after the 3rd injection treatment with Sunekos 200), T2M (after 2 months), T3M (after 3 months)

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

female sex,
30-65 years,
dark circles,
available and able to return to the study site for the post-procedural follow-up examinations;
agreeing to present at each study visit without make-up;
accepting to not change their habits regarding food, physical activity, make-up use, face cosmetic and cleansing products;
accepting not to expose their face to strong UV irradiation (UV session, or sun bathes) during the entire duration of the study, without appropriate sun protection;
accepting to sign the informed consent form

Exclusion Criteria:

Pregnancy;
lactation;
smokers;
alcohol or drug abusers;
subjects not in menopause who do not use adequate contraceptive precautions in order to avoid pregnancies during the study;
subjects not in menopause who do not accept to perform the pregnancy test at T0 (before the 1st aesthetic procedure) and at T3i (1 month after the 1st injection treatment execution, before the 3rd aesthetic procedure);
Body Mass Index (BMI) variation (± 1) during the study period;
performing skin treatments for aesthetic correction (biomaterials implants, face lifting, botox injections, laser, chemical peeling) in the 6 months prior to the study start;
performing permanent filler in the past;
change in the normal habits regarding food, physical activity, face cosmetic, cleansing and make-up use during the month preceding the test;
sensitivity to the test product or its ingredients (to be assessed by the investigator during the baseline visit);
subjects whose insufficient adhesion to the study protocol is foreseeable;
participation in a similar study currently or during the previous 9 months.
Dermatitis;
presence of cutaneous disease on the tested area, as lesions, scars, malformations;
recurrent facial/labial herpes;
clinical and significant skin condition on the test area (e.g. active eczema, psoriasis, severe rosacea, scleroderma, local infections and severe acne).
Diabetes;
endocrine disease;
hepatic disorder;
renal disorder;
cardiac disorder;
pulmonary disease;
cancer;
neurological or psychological disease;
inflammatory/immunosuppressive disease;
drug allergy.
Anticoagulants and antiplatelet drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago);
using of drugs able to influence the test results in the investigator opinion.